文献速递膀胱癌与上尿路尿路上皮癌

UriMee模型:基于甲基化的尿路上皮癌早期诊断工具的开发与验证

Development and Validation of the UriMee Model: A Methylation-based Diagnostic Tool for Early Diagnosis of Urothelial Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2025-04-15

本研究通过整合公共数据集与仁济医院队列,筛选尿路上皮癌特异性DNA甲基化生物标志物,采用LASSO回归在322例模型队列中构建UriMee诊断模型,并在131例独立队列中验证。模型在30%阈值概率下敏感性和特异性均为92%,对早期肿瘤及上尿路尿路上皮癌检测表现优异,显著优于尿脱落细胞学。

要点

  • UriMee模型在30%阈值概率下诊断尿路上皮癌的敏感性和特异性均为92%。
  • 模型对早期肿瘤敏感性高:Ta期83%、T1期93%、Tis期100%。
  • 模型检测上尿路尿路上皮癌敏感性达96%,显著优于尿脱落细胞学。

核心结论

  • UriMee模型在尿路上皮癌诊断中表现出高敏感性和特异性,尤其在早期肿瘤和上尿路尿路上皮癌检测中显著优于传统方法。

研究设计与样本

  • 研究结合TCGA和GEO公共数据集与仁济医院队列(n=50)鉴定UC特异性DNA甲基化标志物。
  • 采用LASSO回归在模型队列(n=322)中构建UriMee诊断模型,并在独立队列(n=131)中验证。

主要发现

  • 在30%阈值概率下,UriMee模型区分UC的敏感性为92%,特异性为92%。
  • 模型对早期肿瘤敏感性:Ta期83%、T1期93%、Tis期100%。
  • 模型检测上尿路尿路上皮癌的敏感性为96%。
  • 与尿脱落细胞学相比,模型敏感性显著更高(90% vs 25%,p < 0.001),特异性相当。

临床怎么用

  • UriMee模型可作为无创诊断工具用于尿路上皮癌的早期诊断,尤其适用于低级别肿瘤和上尿路尿路上皮癌的检测。

局限性

  • 需要更大规模的多中心研究和长期随访来验证研究结果,并评估该检测在不同人群中的有效性及在疾病进展和复发监测中的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Urothelial carcinoma (UC) is a common malignancy that imposes a significant health care burden. Current diagnostic methods are limited by their invasiveness and low sensitivity, particularly for detecting low-grade tumors. Noninvasive, accurate, and reliable diagnostic tests for an early diagnosis of UC are urgently needed. METHODS: UC-specific DNA methylation biomarkers were identified by combining public datasets from The Cancer Genome Atlas and Gene Expression Omnibus with a cohort from Renji Hospital (n = 50). Using the Least Absolute Shrinkage and Selection Operator regression, we developed a diagnostic model, termed the UriMee model, by selecting key biomarkers from a model cohort (n = 322) and subsequently validating it in an independent cohort (n = 131). The diagnostic performance of the assay was evaluated and compared with that of urine cytology. KEY FINDINGS AND LIMITATIONS: At 30% threshold probability, the UriMee model demonstrated high sensitivity (92%) and specificity (92%) in distinguishing UC cases, with particularly strong performance in early-stage tumors (83% sensitivity for Ta, 93% for T1, and 100% for Tis). It significantly outperformed urine cytology, offering greater sensitivity (90% vs 25%, p < 0.001) while maintaining comparable specificity. Additionally, the model was highly effective in identifying upper tract urothelial carcinoma (UTUC), achieving sensitivity of 96%. The study's limitations include the necessity for larger multicenter studies and long-term follow-up to validate the findings and assess the test's effectiveness across diverse populations, as well as its utility in monitoring disease progression and recurrence. CONCLUSIONS: The UriMee test demonstrated high sensitivity and specificity, particularly in detecting early-stage tumors and UTUC, significantly outperforming traditional methods.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Cao M, Yang G, Zhao T, et al. Development and Validation of the UriMee Model: A Methylation-based Diagnostic Tool for Early Diagnosis of Urothelial Carcinoma. Eur Urol Oncol. 2025. PMID: 40240254. doi:10.1016/j.euo.2025.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。